Esperion Therapeutics ESPR reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Esperion Therapeutics beat estimated earnings by 12.9%, reporting an EPS of $-0.81 versus an estimate of $-0.93.
Revenue was up $4.57 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.12 which was followed by a 1.7% drop in the share price the next day.
Here's a look at Esperion Therapeutics's past performance:
|Quarter||Q2 2022||Q1 2022||Q4 2021||Q3 2021|
To track all earnings releases for Esperion Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.